Guardant Health, Inc. (GH) Stock: Price, Forecast & Analyst Target
Guardant Health, Inc. (GH) — MoonshotScore 35/100 (Weak band), calculated Oct 4, 2026. Price $177.80 (+1.75%), as of the Oct 2, 2026 trading session; market cap $23.9B. Expected results Oct 28, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 22.69× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 28, 2026
Guardant Health, Inc. · GH · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Guardant Health sells liquid-biopsy and tissue-based oncology tests, cancer screening, clinical-genomic analytics and development services for biopharma customers. Revenue is expanding quickly, but screening investment and rising operating expense still keep cash flow negative; durability depends on closing that gap without exhausting the balance-sheet cushion.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Guardant Health (GH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Average across the board, but the score sits below the pillars — the real driver is off the card; nothing here stands out either way, so treat with caution. Business Quality: Solid; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $335M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 2 of 8
- Altman Z 4.83 · Piotroski F 4
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak |
The score was 35 in the stored Oct 3, 2026 snapshot and remains 35 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $177.80 | |
| Change on the day | +1.75% | |
| 52-week range | $61.00 – $183.51 | |
| Market capitalisation | $23.9B | |
| Price / earnings (trailing) | -243.47 | |
| Shares traded on the day | 1.65M | |
| Beta (volatility vs the S&P 500) | 1.58 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to be excited about the commercial momentum behind Reveal, and we remain on track to launch Reveal Ultra later this year, which we believe will be the most sensitive tumor-informed MRD test.
Helmy Eltoukhy · Statement from
As a result, we now expect 2026 non-GAAP operating expenses of $1.08 billion to $1.1 billion, representing growth of 20% to 22% compared with 2025.
Michael Bell · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Guardant Health (GH): Split View
44/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the GH film — every key number, told as a short cinematic story
~2 min · open the film
What is Guardant Health (GH), and what does it report?
Short answer · as of
Guardant is a precision-oncology platform rather than a developer of cancer medicines.
Research dated 2026-09-12.
Guardant is a precision-oncology platform rather than a developer of cancer medicines. It earns revenue from testing patients with advanced or early-stage cancer, screening asymptomatic people, supplying clinical-genomic analytics, and supporting biopharma customers with companion diagnostics and clinical development services.
Reported revenue primarily reflects Oncology, Biopharma & Data, and the emerging Screening business, with licensing and other activity contributing little. Oncology remains the commercial base, while Screening and data services expose the company to distinct adoption cycles and spending requirements.
What do the latest results show for Guardant Health (GH)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $335M.
Research dated 2026-09-12.
The latest quarter extended the revenue climb across the displayed history, and gross profit rose with it. Operating and net losses nevertheless widened from the preceding period as selling and administrative expense climbed and research spending remained heavy. Revenue has also cleared consensus throughout the earnings history shown, while per-share results have been uneven.
Management’s outlook calls for further expense growth, says the business outside Screening should generate positive free cash flow, and retains a companywide cash-flow breakeven goal. That framing identifies Screening as the principal bridge between strong commercial momentum and the intended cash profile.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $334.98M Jun 30, 2026
- Latest quarter · R&D
- $96.53M Jun 30, 2026
- Latest quarter · SG&A
- $251.61M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$129.12M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $334.98M | $96.53M | $251.61M | −$129.12M |
| Mar 31, 2026 | $301.67M | $91.04M | $227.06M | −$121.35M |
| Dec 31, 2025 | $281.27M | $98.26M | $204.31M | −$120.81M |
| Sep 30, 2025 | $265.20M | $89.96M | $180.64M | −$98.99M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $334.98M Jul 30, 2026
- Latest report · revenue estimate
- $314.23M Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Below estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $334.98M | $314.23M | −$0.9000 | −$0.7618 |
| May 7, 2026 | $301.67M | $279.15M | −$0.8500 | −$0.8060 |
| Feb 19, 2026 | $281.27M | $272.42M | −$1.0000 | −$0.7668 |
| Oct 29, 2025 | $265.20M | $235.61M | −$0.7400 | −$0.7896 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $335M | -$120M | -$0.90 (diluted) |
| Q1 FY2026 | $302M | -$112M | -$0.85 (diluted) |
| Q4 FY2025 | $281M | -$128M | -$1.00 (diluted) |
| Q3 FY2025 | $265M | -$93M | -$0.74 (diluted) |
What are the financial strengths and risks for Guardant Health (GH)?
Short answer
Cash and short-term investments were $1.05B at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$57.78M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Cash and investments provide substantial operating runway at the recent pace of cash use, and near-term liquidity ratios remain strong. The company is not in a net-cash position, however: debt exceeds cash and short-term investments, while operations and capital spending continue to consume cash.
Management’s carve-out of Screening from expected positive free cash flow makes that business the visible funding burden. If commercial growth slows while selling expense remains elevated, persistent losses could continue despite healthy gross margins and ample liquidity.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$57.78M Jun 30, 2026
- Previous quarter · operating cash flow
- −$65.62M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$57.78M | −$11.76M |
| Mar 31, 2026 | −$65.62M | −$5.58M |
| Dec 31, 2025 | −$26.37M | −$27.85M |
| Sep 30, 2025 | −$35.41M | −$10.35M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Guardant Health (GH)?
Short answer · as of
The next earnings report is expected on Oct 28, 2026.
Research dated 2026-09-12.
Consensus expects another revenue step-up and a much smaller per-share loss at the scheduled earnings release. Delivery on revenue without a corresponding improvement in operating loss or cash use would repeat the pattern already visible in recent results.
Reveal Ultra provides the near-term product marker. Launch progress and continued Reveal momentum should be read alongside segment mix and cash generation: Screening must become less burdensome while Oncology and Biopharma & Data sustain the commercial base.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We continue to be excited about the commercial momentum behind Reveal, and we remain on track to launch Reveal Ultra later this year, which we believe will be the most sensitive tumor-informed MRD test.
Helmy Eltoukhy ·
As a result, we now expect 2026 non-GAAP operating expenses of $1.08 billion to $1.1 billion, representing growth of 20% to 22% compared with 2025.
Michael Bell ·
We continue to expect the rest of the business, excluding Screening, to generate positive free cash flow in 2026, with year-over-year improvements in cash generation, and we remain committed to achieving company-wide cash flow breakeven by the end of 2027.
Michael Bell ·
How does Guardant Health compare with its peers?
Short answer
Guardant Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Guardant combines advanced-cancer liquid biopsy, residual-disease testing, cancer screening and biopharma analytics built around a clinical-genomic dataset. Unlike a drug developer, it sells tests, datasets and development support rather than depending on sales of a therapy.
Compared with a testing-only laboratory, GuardantINFORM and companion-diagnostic services make biopharma research clients part of the model. That breadth creates distinct routes to adoption, but it also requires concurrent spending across established oncology products and the newer Screening business.
| Company | Price | Market value | Score |
|---|---|---|---|
| $273.04 Oct 2, 2026 | $41.3B | 94 5-pillar Oct 4, 2026 | |
| $599.47 Oct 2, 2026 | $16.7B | 92 5-pillar Oct 4, 2026 | |
| $518.39 Oct 2, 2026 | $40.9B | 92 5-pillar Oct 4, 2026 | |
| $227.87 Oct 2, 2026 | $14.2B | 88 5-pillar Oct 4, 2026 | |
| $1486.19 Oct 2, 2026 | $30.0B | 82 5-pillar Oct 4, 2026 | |
| $233.24 Oct 2, 2026 | $25.7B | 74 5-pillar Oct 4, 2026 | |
| $258.21 Oct 2, 2026 | $42.5B | 73 5-pillar Oct 4, 2026 | |
| $308.49 Oct 2, 2026 | $25.3B | 71 5-pillar Oct 4, 2026 | |
| $151.53 Oct 2, 2026 | $16.9B | 71 5-pillar Oct 4, 2026 | |
| $425.21 Oct 2, 2026 | $41.8B | 64 5-pillar Oct 4, 2026 | |
| $290.19 Oct 2, 2026 | $14.0B | 62 5-pillar Oct 4, 2026 | |
| $87.85 Oct 2, 2026 | $15.2B | 61 5-pillar Oct 4, 2026 | |
| Guardant Health (GH) — this page | $177.80 | $23.9B | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $180.00 – $225.00
- Consensus target
- $200.07
- Median target
- $200.00
Consensus record · Captured .
Measured against a quoted price of $177.80 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 60
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 60
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 626 Period end Jun 30, 2026
- Previous quarter · holders
- 510 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 7,622,935 |
| Price T Rowe Associates INC /Md/ | 6,514,952 |
| Vanguard Capital Management LLC | 5,755,857 |
| Fmr LLC | 5,488,272 |
| Vanguard Portfolio Management LLC | 5,445,785 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Guardant Health (GH)?
What Investors Ask About Guardant Health (GH) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Reveal Ultra add to Guardant Health’s residual-disease strategy?
Management presents Reveal Ultra as a more sensitive tumor-informed residual-disease test and pairs its planned launch with continued commercial momentum for Reveal. Its importance lies in adoption within early-stage cancer care, rather than merely expanding the advanced-cancer assay menu.
Why does Screening matter so much to Guardant Health’s cash burn?
Management expects the business outside Screening to generate positive free cash flow while consolidated operations remain cash-consuming. That carve-out makes Screening the key funding burden to track as revenue scales.
What does GuardantINFORM sell to biopharma customers?
GuardantINFORM turns the company’s clinical-genomic liquid-biopsy dataset into an in-silico research platform. It extends the business from processing patient tests into supplying analytical utility to research and clinical clients.
Why have Guardant Health’s revenue beats not produced profits?
Revenue has repeatedly exceeded estimates, but selling, administrative and research spending remain above gross profit, leaving operating and net results negative. The widening latest loss shows that top-line momentum has not yet delivered operating leverage.
What is the GH stock price today?
The last price recorded on this page for Guardant Health, Inc. (GH) is $177.80, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GH price target?
The analyst consensus price target for Guardant Health, Inc. (GH) is $200.07 (range $180.00 to $225.00, median $200.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Helmy Eltoukhy (Jul 30, 2026): We continue to be excited about the commercial momentum behind Reveal, and we remain on track to launch Reveal Ultra later this year, which we believe will be the most sensitive tumor-informed MRD test. Michael Bell (Jul 30, 2026): As a result, we now expect 2026 non-GAAP operating expenses of $1.08 billion to $1.1 billion, representing growth of 20% to 22% compared with 2025. Michael Bell (Jul 30, 2026): We continue to expect the rest of the business, excluding Screening, to generate positive free cash flow in 2026, with year-over-year improvements in cash generation, and we remain committed to achieving company-wide cash flow breakeven by the end of 2027. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Palo Alto, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "3100 Hanover Street, Palo Alto, CA, 94304, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 28, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $177.80 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:38.342Z. | |
px.change | Change on the day | +1.75% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $23.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:37.405Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$3.05 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $335M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -243.47 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.65M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.58 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Helmy Eltoukhy | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 2,498 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $373.65M, net result −$405.67M; FY2022 revenue $449.54M, net result −$654.59M; FY2023 revenue $563.95M, net result −$479.45M; FY2024 revenue $739.02M, net result −$436.37M; FY2025 revenue $982.02M, net result −$416.28M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Oncology $683.60M · Screening $79.73M · Biopharma & Data $210.13M · Licensing & Other $8.56M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 65.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $334.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $96.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $251.61M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$129.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $301.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $91.04M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $227.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$121.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $281.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $98.26M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $204.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$120.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $265.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $89.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $180.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$98.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $334.98M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $314.23M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | −$0.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | −$0.7618 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $301.67M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $279.15M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.8500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.8060 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.revenue_actual | Revenue · reported — report date 2026-02-19 | $281.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.revenue_estimated | Revenue · estimate — report date 2026-02-19 | $272.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_actual | EPS · reported — report date 2026-02-19 | −$1.0000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_estimated | EPS · estimate — report date 2026-02-19 | −$0.7668 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-29.revenue_actual | Revenue · reported — report date 2025-10-29 | $265.20M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-29.revenue_estimated | Revenue · estimate — report date 2025-10-29 | $235.61M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-29.eps_actual | EPS · reported — report date 2025-10-29 | −$0.7400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-29.eps_estimated | EPS · estimate — report date 2025-10-29 | −$0.7896 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.05B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$57.78M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $120.77M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.70B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$57.78M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$65.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$11.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$5.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$26.37M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$27.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$35.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$10.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $180.00 – $225.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $200.07 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $200.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 0 sales, 60 other transactions · 8 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 626 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 510 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 7,622,935 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 6,514,952 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Capital Management LLC — shares in provider snapshot | 5,755,857 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fmr LLC — shares in provider snapshot | 5,488,272 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 5,445,785 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 4.83 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
px.range52 | 52-week range | $61.00 – $183.51 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 22.69× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.05B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($334.98M) with the recorded estimate ($314.23M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.9000) with the recorded estimate (−$0.7618) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 35 of 100 · Weak · pillars 65 / 42 / 56 / 63 / 97 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 35 (stored snapshot Oct 3, 2026) → 35 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-19.revenue_actual,earn.history.depth.2026-02-19.revenue_estimated,earn.history.depth.2026-02-19.eps_actual,earn.history.depth.2026-02-19.eps_estimated,earn.history.depth.2025-10-29.revenue_actual,earn.history.depth.2025-10-29.revenue_estimated,earn.history.depth.2025-10-29.eps_actual,earn.history.depth.2025-10-29.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Oncology: $683.60M; Screening: $79.73M; Biopharma & Data: $210.13M; Licensing & Other: $8.56M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $1.70B; Liquidity basis: cash and short-term investments; Total liabilities: $2.14B; Cash and short-term investments: $1.05B; Cash and investments: $1.17B; Long-term investments: $120.77M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 8071 — Services-Medical Laboratories. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 3 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-30 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.17B; Cash and short-term investments: $1.05B; Long-term investments: $120.80M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 4.1; Method: cash and short-term investments of $1053.5M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($256.2M per year); Reaches: 2030-07; Cash basis: cash and short-term investments; Cash: $1.05B; Annualized cash use: $256.20M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$643.50M; Total debt: $1.70B; Cash and investments: $1.05B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 3.71; Current ratio: 4.03; Debt to equity: -7.61; Net margin: -38.3%; Gross margin: 65%; Operating margin: -39.7%; Return on assets: -23.7%; Return on equity: 211.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-28; EPS estimate: -$0.29 per share; Revenue estimate: $350.79M The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.
ETFs that hold GH
Funds in our ETF coverage that list GH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 4.71% |